SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2026)
SAB Biotherapeutics (SABS) posted Retained Earnings of -$129.8 million for Q1 2026, down 17.05% on a QoQ basis from -$110.9 million in Q4 2025, and little changed year-over-year from -$130.2 million in Q1 2025.
SAB Biotherapeutics (SABS) Retained Earnings (2020 - 2026) Analysis & Trends
SAB Biotherapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$129.8 million for Q1 2026.
- Quarterly Retained Earnings changed 0.34% year-over-year to -$129.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$129.8 million (changed 0.34% YoY) and the FY2025 annual result came in at -$110.9 million, down 171.18% from the prior year.
- Retained Earnings was -$129.8 million for Q1 2026 at SAB Biotherapeutics, down from -$110.9 million in the prior quarter.
- Across five years, Retained Earnings topped out at $157.0 million in Q2 2025 and bottomed at -$129.8 million in Q1 2026.
- A 5-year average of -$23.1 million and a median of -$62.1 million in 2023 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 943.01% in 2022, while the deepest fall reached 316.28% in 2022.
- SAB Biotherapeutics' Retained Earnings stood at -$47.9 million in 2022, then slumped by 88.14% to -$90.1 million in 2023, then soared by 272.98% to $155.8 million in 2024, then sank by 171.18% to -$110.9 million in 2025, then decreased by 17.05% to -$129.8 million in 2026.
- Business Quant data shows SABS's Retained Earnings at -$129.8 million in Q1 2026, -$110.9 million in Q4 2025, and -$94.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | -129.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.80 Mn |
| Dec 31, 2025 | -110.90 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Jun 30, 2025 | 157.03 Mn |
| Mar 31, 2025 | -129.37 Mn |
| Dec 31, 2024 | 155.79 Mn |
| Sep 30, 2024 | 155.14 Mn |
| Jun 30, 2024 | -102.42 Mn |
| Mar 31, 2024 | -95.09 Mn |
| Dec 31, 2023 | -90.06 Mn |
| Sep 30, 2023 | -67.21 Mn |
| Jun 30, 2023 | -62.10 Mn |
| Mar 31, 2023 | -55.22 Mn |
| Dec 31, 2022 | -47.87 Mn |
| Sep 30, 2022 | 76.14 Mn |
| Jun 30, 2022 | 75.56 Mn |
| Mar 31, 2022 | -28.14 Mn |
| Dec 31, 2021 | 67.67 Mn |
| Sep 30, 2021 | -9.29 Mn |
| Jun 30, 2021 | -8.96 Mn |